Products
2660 products
Code | Description | Unit |
---|---|---|
EPY0001261 | Lufenuron for peak identification | EP unit |
EPY0001262 | Flucytosine for system suitability | EP unit |
EPY0001263 | Etacrynic acid for system suitability | EP unit |
EPY0001264 | Aciclovir for system suitability | EP unit |
EPY0001265 | Lufenuron impurity G - 2,5-dichloro-4-[[[(2,6-difluorophenyl)carbonyl]carbamoyl] amino]phenyl phenyl carbonate | EP unit |
EPY0001266 | Pramipexole dihydrochloride monohydrate | EP unit |
EPY0001267 | Pramipexole impurity D - (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine | EP unit |
EPY0001268 | Nicotinic acid impurity mixture | EP unit |
EPY0001269 | Aciclovir for peak identification 2 | EP unit |
EPY0001270 | Timolol for system suitability | EP unit |
EPY0001271 | Aciclovir for peak identification 1 | EP unit |
EPY0001272 | Ziprasidone for system suitability 1 | EP unit |
EPY0001273 | Baicalin | EP unit |
EPY0001274 | Flecainide for system suitability | EP unit |
EPY0001275 | Potassium sucrose octasulfate | EP unit |
EPY0001276 | Risperidone impurity K - 3-[2-[4-(1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one (desfluoro risperidone) | EP unit |
EPY0001277 | Hydroxyethyl starch (medium MW) | EP unit |
EPY0001278 | Nizatidine for system suitability | EP unit |
EPY0001279 | Galantamine hydrobromide | EP unit |
EPY0001280 | Gabapentin | EP unit |
EPY0001281 | Gabapentin impurity A - 2-azaspiro[4.5]decan-3-one | EP unit |
EPY0001282 | Heparin for physio-chemical analysis | EP unit |
EPY0001283 | Heparin sodium for system suitability | EP unit |
EPY0001284 | Lufenuron | EP unit |
EPY0001285 | Sertraline impurity E | EP unit |
EPY0001286 | Ziprasidone hydrochloride monohydrate | EP unit |
EPY0001287 | Heparin calcium for NMR identification | EP unit |
EPY0001288 | Salbutamol sulfate for system suitability | EP unit |
EPY0001289 | Magnolol | EP unit |
EPY0001291 | Iodixanol impurity E - 5-[acetyl[3-[acetyl[3-carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide | EP unit |
EPY0001292 | Iodixanol impurity C - 5-[acetyl[3-[[3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide | EP unit |
EPY0001293 | Iodixanol impurity H - 5-[acetyl[3-[acetyl[3-[[3-[3-[acetyl[3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropoxy]-2-hydroxypropyl]carbamoyl]-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropyl]amino]- | EP unit |
EPY0001294 | Iodixanol | EP unit |
EPY0001295 | Spironolactone for system suitability | EP unit |
EPY0001296 | Nortriptyline for system suitability | EP unit |
EPY0001297 | Iopentol | EP unit |
EPY0001298 | Chlorambucil for system suitability | EP unit |
EPY0001299 | Chlorambucil with impurity G | EP unit |
EPY0001300 | Sodium cromoglicate for system suitability | EP unit |
EPY0001301 | Norfloxacin for peak identification | EP unit |
EPY0001302 | Rizatriptan benzoate | EP unit |
EPY0001303 | Rizatriptan for system suitability | EP unit |
EPY0001304 | Butyl methanesulfonate | EP unit |
EPY0001305 | Cefpodoxime proxetil | EP unit |
EPY0001306 | Cefpodoxime proxetil for peak identification | EP unit |
EPY0001308 | Glycopyronium bromide | EP unit |
EPY0001309 | Glycopyrronium for peak identification | EP unit |
EPY0001310 | Meclozine impurity B - 4-chlorobenzhydrol | EP unit |
EPY0001311 | Meclozine impurity H - 1-(4-chlorobenzhydryl)piperazine | EP unit |
EPY0001312 | Testosterone enantate for peak identification | EP unit |
EPY0001313 | Testosterone enantate impurity H - delta-5-testosterone-3,17-dienantate | EP unit |
EPY0001314 | 1-Nonadecanol | EP unit |
EPY0001315 | Josamycin for peak identification | EP unit |
EPY0001316 | Tropicamide for peak identification | EP unit |
EPY0001317 | Testosterone enantate for system suitability | EP unit |
EPY0001318 | Cefpodoxime proxetil for impurity H identification | EP unit |
EPY0001319 | Trimebutine maleate | EP unit |
EPY0001320 | Ondansetron impurity F | EP unit |
EPY0001321 | Dermatan sulfate and oversulfated chondroitin sulfate | EP unit |
EPY0001322 | Hydroxyethyl starch (high Mw) | EP unit |
EPY0001323 | Aristolochia | EP unit |
EPY0001324 | Sucralfate | EP unit |
EPY0001325 | Equisetum palustre | EP unit |
EPY0001326 | Ondansetron impurity E - Imidazole | EP unit |
EPY0001327 | Atorvastatine calcium trihydrate | EP unit |
EPY0001328 | Atorvastatin impurity A - desfluoroatorvastatin | EP unit |
EPY0001329 | Atorvastatin impurity B - 3-epi-atorvastatin | EP unit |
EPY0001330 | Atorvastatin impurity C - fluoroatorvastatin | EP unit |
EPY0001331 | Atorvastatin impurity D - 3-[(4-fluorophenyl)carbonyl]-2-(2-methylpropanoyl)-N,3-diphenyloxirane-2-carboxamide | EP unit |
EPY0001332 | Atorvastatin impurity E - ent-atorvastatin | EP unit |
EPY0001333 | Clopidogrel hydrogen sulfate (Clopidogrel hydrogen sulfate) | EP unit |
EPY0001334 | Clopidogrel for system suitability (Clopidogrel hydrogen sulfate) | EP unit |
EPY0001335 | Clopidogrel impurity A - (2S)-(2-chlorophenyl)[6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]acetic acid | EP unit |
EPY0001336 | Cefepime impurity E - (6R,7R)-7-amino-3-[(1-methylpyrrolidinio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | EP unit |
EPY0001337 | Oseltamivir phosphate impurity B - free | EP unit |
EPY0001338 | Oseltamivir impurity A - (3R,4R,5S)-5-acetamido-4-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid | EP unit |
EPY0001339 | Oseltamivir impurity B - ethyl (1R,2R,3S,4R,5S)-4-acetamido-5-amino-2-azido-3- (1-ethylpropoxy)cyclohexanecarboxylate | EP unit |
EPY0001340 | Oseltamivir impurity C - (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid | EP unit |
EPY0001341 | Oseltamivir impurity H - tributylphosphane oxide | EP unit |
EPY0001342 | Sucralose impurity B - 1,6-dichloro-1,6-dideoxy-beta-D-fructofuranoxyl 6-chloro-6-deoxy-alpha-D-glucopyfranoside (1',6,6'-trichloro-1',6,6'-trideoxysucrose | EP unit |
EPY0001344 | Sucralose | EP unit |
EPY0001345 | Ondansetron impurity A - (3RS)-3-[(dimethylamino)methyl]-9-methyl-1,2,3,9- tetrahydro-4H-carbazol-4-one | EP unit |
EPY0001346 | Ondansetron impurity G - (3RS)-3-[(1H-imidazol-1-yl)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one (C-demethylondansetron) | EP unit |
EPY0001347 | Ginsenoside Rb1 | EP unit |
EPY0001348 | Gabapentin impurity B - (1-cyanocyclohexyl)acetic acid | EP unit |
EPY0001349 | Gabapentin impurity D - [1-[(3-oxo-2-azaspiro[4.5]dec-2-yl)methyl]cyclohexyl]acetic acid | EP unit |
EPY0001350 | Phenobarbital impurity A - (5RS)-5-ethyl-2,6-diimino-5-phenyltetrahydropyrimidin-4(1H)-one | EP unit |
EPY0001351 | Phenobarbital impurity B - (5RS)-5-ethyl-6-imino-5-phenyldihydropyrimidine-2,4(1H,3H)-dione | EP unit |
EPY0001352 | Nicergoline for system suitability | EP unit |
EPY0001354 | Betaxolol impurity C - 2-[[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]methyl]oxirane *** | EP unit |
EPY0001355 | Prednisolone for system suitability | EP unit |
EPY0001356 | Nicergoline impurity D - 5-bromopyridine-3-carboxylic acid | EP unit |
EPY0001357 | Butyl parahydroxybenzoate impurity E - 2-methylpropyl 4-hydroxybenzoate (iso-butyl parahydroxybenzoate) | EP unit |
EPY0001358 | Glycopyrronium impurity N - (3RS)-3-[(2RS)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium | EP unit |
EPY0001359 | Prednisolone for peak identification | EP unit |
EPY0001360 | Betaxolol for peak identification | EP unit |
EPY0001361 | Amphotericin B for microbiological assay | EP unit |
EPY0001362 | Nicergoline for peak identification | EP unit |
EPY0001363 | Gentamicin for peak identification | EP unit |
EPY0001365 | Etoposide for peak identification | EP unit |